NY-ESO-1/IL-12-expressing autologous lymphocytes (National Cancer Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNY-ESO-1/IL-12-expressing autologous lymphocytes (National Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapyCell and gene therapy > Gene therapy

Mechanisms of ActionCancer/testis antigen 1 modulatorsInterleukin-12 modulators

TargetsInterleukin-12Cancer/testis antigen 1

Therapy Area/IndicationsNeoplasm Metastasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A